ArticleOncology letters2017
Clinical significance of ALDH1 combined with DAPI expression in patients with esophageal carcinoma.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Clinical significance of ALDH1A1 and Ki67 expression in women with breast carcinoma.Histology and histopathology · 2025Article
- 3D tumor spheroids: morphological alterations a yardstick to anti-cancer drug response.In vitro models · 2023Review
- In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma.BMC cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma is the most common type of tumor, with the incidence in China accounting for 50% of cases worldwide and the majority of patients not surviving due to tumor recurrence. According to the cancer stem cell theory, tumor development and recurrence is due to the excitation of a cancer stem cell. Aldehyde dehydrogenase 1 (ALDH1) is an appropriate marker for cancer stem cells and the present study aimed at determining the function of ALDH1 in human esophageal carcinoma. Indirect fluorescence antibody staining was used to investigate the association between the level of ALDH1 protein expression and clinicopathological parameters, including sex, age, vein invasion, degree of tumor cell differentiation and clinical stage. DAPI was used to stain the nuclei of tumor cells and exclude non-tumor cells. The results of the present study revealed that ALDH1 expression was associated with the level of tumor cell differentiation, tumor-node-metastasis stage and lymphatic invasion. In addition, increased expression of ALDH1 was identified in esophageal carcinoma tissues compared with in healthy esophageal tissues. Therefore, ALDH1 may be used as a parameter for the pathology of esophageal carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.